Ophthalmic Solution
[INQ. NO. 2311C01] CKD Ranibizumab (Code No.: CKD-701), also known as Ranibizumab Biosimilar, emerges as a beacon of hope for those plagued with macular degeneration. Macular degeneration, an ailment where the eye’s macula deteriorates due to aging and inflammation, can lead to severe visual impairment. As the global population continues to age, the number of patients affected by this condition is on the rise.

The CKD-701 works by binding with the Vascular Endothelial Growth Factor (VEGF), suppressing the abnormal growth of blood vessels and preventing fluid leakage. This, in turn, halts vision deterioration and even aids in its restoration.

Clinical trials have validated its efficacy, showing it to be on par with comparable drugs. Furthermore, its safety profile, with similar adverse reaction rates and immunogenicity, reinforces its standing as a reliable treatment option.
When juxtaposed with competitive ingredients, the superiority of CKD-701 is evident. Its smaller molecular size ensures better penetration through the retinal pigment epithelium. Moreover, its heightened affinity for VEGF guarantees a longer effective duration post-injection.

With five indications, compared to the single indication of competitors like Aflibercept or Brolucizumab, its therapeutic range is broader, making it suitable for treating conditions like diabetic macular edema.
Chong Kun Dang Pharmaceutical Corp. is a pharmaceutical magnate in South Korea. Utilizing its proprietary biosimilar platform technology, it successfully developed the high-yielding strain for CKD-701. This self-developed drug, encompassing everything from raw materials to the finished product, boasts a price competitiveness, being over 50% more affordable than its original counterparts.
With the introduction of the high-purity CKD-701(CKD Ranibizumab), global patients now have a wider range of treatment options and can anticipate reduced treatment expenses.

Korean-Products.com | Blog Magazine of Korean products, brands and Goods